NCT05205070 - A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

January 19, 2023

Study Completion Date

March 19, 2023

Conditions

Alopecia Areata

Interventions

BIOLOGICAL

Rosnilimab

humanized monoclonal antibody

BIOLOGICAL

Placebo

Placebo solution

Trial Locations (16)

10029

RECRUITING

Site 10-111, New York

15241

RECRUITING

10-107, Upper Saint Clair

28277

RECRUITING

Site 10-101, Charlotte

35205

RECRUITING

10-105, Birmingham

40241

RECRUITING

Site 10-116, Louisville

43208

RECRUITING

Site 10-102, Bexley

46168

RECRUITING

Site 10-109, Plainfield

46250

RECRUITING

10-104, Indianapolis

48346

RECRUITING

Site 10-117, Clarkston

53144

RECRUITING

Site 10-114, Kenosha

60611

RECRUITING

Site 10-115, Chicago

74136

RECRUITING

Site 10-106, Tulsa

77056

RECRUITING

10-110, Houston

78229

RECRUITING

Site 10-108, San Antonio

91324

RECRUITING

Site 10-113, Northridge

92024

RECRUITING

Site10-103, Encinitas